NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

BCDA

BioCardia Inc

May 01 • 04:00PM ET

2.85

Dollar change -0.29
Percentage change -9.24	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-3.34	Insider Own	21.10%	Shs Outstand	4.60M	Perf Week	57.02%
Market Cap	14.52M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	54.06%	Shs Float	3.69M	Perf Month	33.18%
Income	-7.95M	PEG	-	EPS next Q	-	Inst Own	3.43%	Short Float	1.08%	Perf Quarter	22.84%
Sales	0.06M	P/S	242.00	EPS this Y	65.52%	Inst Trans	27.55%	Short Ratio	0.52	Perf Half Y	8.37%
Book/sh	0.18	P/B	15.67	EPS next Y	10.00%	ROA	-236.81%	Short Interest	0.04M	Perf Year	-48.65%
Cash/sh	0.47	P/C	6.13	EPS next 5Y	-	ROE	-737.89%	52W Range	1.62 - 6.15	Perf YTD	30.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.58%	ROI	-566.36%	52W High	-53.66%	Beta	0.95
Dividend TTM	-	Quick Ratio	1.13	Sales past 5Y	80.21%	Gross Margin	-641.38%	52W Low	75.38%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	1.13	EPS Y/Y TTM	59.34%	Oper. Margin	-13794.83%	RSI (14)	63.56	Volatility	16.24% 9.85%
Employees	20	Debt/Eq	1.13	Sales Y/Y TTM	-87.84%	Profit Margin	-13700.00%	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	0.68	EPS Q/Q	62.00%	Payout	-	Rel Volume	1.51	Prev Close	3.14
Sales Surprise	11.11%	EPS Surprise	90.40%	Sales Q/Q	-100.00%	Earnings	Mar 26 AMC	Avg Volume	76.81K	Price	2.85
SMA20	34.18%	SMA50	22.41%	SMA200	15.09%	Trades		Volume	116,371	Change	-9.24%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
09:15AM	Loading…
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
09:15AM	Loading…
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
08:30AM	Loading…
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 (GlobeNewswire)
Jul-24-23 07:00AM	BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected (GlobeNewswire) -44.70%
Jul-10-23 08:11AM	Those who invested in BioCardia (NASDAQ:BCDA) a year ago are up 86% (Simply Wall St.)
Jul-05-23 07:00AM	BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japans Pharmaceutical Medical Device Agency (GlobeNewswire)
Jun-20-23 05:14PM	BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire) +6.41% +12.45%
Jun-08-23 07:00AM	BioCardia Announces Helix Biotherapeutic Delivery Patent Issuance in Japan (GlobeNewswire) +6.53%
May-28-23 08:08AM	Joseph Daly Spends US$177k Buying BioCardia Shares \ (Simply Wall St.)
May-23-23 07:00AM	BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire)
May-12-23 06:06AM	BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-10-23 05:45PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	BioCardia Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
May-09-23 07:00AM	BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (GlobeNewswire)
May-03-23 08:00PM	BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023 (GlobeNewswire)
Apr-28-23 07:00AM	BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available (GlobeNewswire)
Apr-04-23 07:00AM	BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies (GlobeNewswire)
Apr-01-23 12:47PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:05AM	We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate (Simply Wall St.)
Mar-29-23 08:15AM	BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023 (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM
Altman Peter	President and CEO	Feb 07 '25	Buy	2.48	600	1,488	107,920	Feb 11 05:42 PM
Altman Peter	President and CEO	Jan 29 '25	Buy	2.40	500	1,200	107,081	Jan 30 08:36 PM
Altman Peter	President and CEO	Jan 30 '25	Buy	2.38	239	569	107,320	Jan 30 08:36 PM
Altman Peter	President and CEO	Dec 23 '24	Buy	2.06	1,000	2,060	106,581	Dec 26 02:30 PM
GILLIS EDWARD M	Senior Vice President, Devices	Dec 20 '24	Sale	2.00	3,257	6,514	8,968	Dec 26 02:30 PM
GILLIS EDWARD M	Officer	Dec 17 '24	Proposed Sale	2.03	3,257	6,611		Dec 17 11:50 AM
Altman Peter	President and CEO	Dec 05 '24	Buy	2.22	250	555	105,581	Dec 09 05:04 PM
Altman Peter	President and CEO	Nov 15 '24	Buy	1.87	1,350	2,524	105,331	Nov 19 08:00 AM
Altman Peter	President and CEO	Jul 01 '24	Buy	3.05	300	915	39,745	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 28 '24	Buy	2.99	200	598	39,445	Jul 02 04:12 PM
Altman Peter	President and CEO	Jun 21 '24	Buy	3.29	500	1,645	39,245	Jun 24 08:46 AM
Altman Peter	President and CEO	Jun 14 '24	Buy	3.52	500	1,760	38,745	Jun 17 07:00 AM
Altman Peter	President and CEO	Jun 10 '24	Buy	3.36	1,000	3,360	38,245	Jun 12 07:00 AM

Dollar change -0.03
Percentage change -2.17	%

Peers: LH DGX MYGN EXAS MEDP CMRX VNDA BCRX TECH CRL

| Held by: VTI VB IWM VXF IWN VBR VBK IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.09	Insider Own	54.83%	Shs Outstand	671.55M	Perf Week	-7.53%
Market Cap	906.59M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	0.76%	Shs Float	303.35M	Perf Month	-18.67%
Income	-53.25M	PEG	-	EPS next Q	-0.11	Inst Own	31.49%	Short Float	11.52%	Perf Quarter	-10.60%
Sales	713.10M	P/S	1.27	EPS this Y	-328.57%	Inst Trans	8.25%	Short Ratio	6.87	Perf Half Y	-10.00%
Book/sh	2.03	P/B	0.66	EPS next Y	37.50%	ROA	-2.53%	Short Interest	34.96M	Perf Year	8.87%
Cash/sh	0.64	P/C	2.10	EPS next 5Y	-11.20%	ROE	-3.87%	52W Range	1.15 - 2.04	Perf YTD	-8.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.04%	ROI	-2.89%	52W High	-33.66%	Beta	1.43
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	1.59%	Gross Margin	19.05%	52W Low	17.39%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	3.43	EPS Y/Y TTM	70.55%	Oper. Margin	-38.36%	RSI (14)	32.53	Volatility	5.17% 5.34%
Employees	2997	Debt/Eq	0.37	Sales Y/Y TTM	-17.42%	Profit Margin	-7.47%	Recom	1.29	Target Price	3.99
Option/Short	Yes / Yes	LT Debt/Eq	0.35	EPS Q/Q	116.61%	Payout	-	Rel Volume	0.88	Prev Close	1.38
Sales Surprise	-8.74%	EPS Surprise	-45.77%	Sales Q/Q	0.93%	Earnings	Apr 30 AMC	Avg Volume	5.09M	Price	1.35
SMA20	-6.10%	SMA50	-17.33%	SMA200	-13.10%	Trades		Volume	4,470,022	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10
Oct-22-12	Initiated	Barrington Research	Outperform	$6
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy	$6 → $8.50

Show Previous Ratings

May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	Loading…
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
08:00AM	Loading…
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Feb-25-25 09:15AM	Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-13-25 04:05PM	OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 (GlobeNewswire)
09:15AM	Loading…
Feb-12-25 09:15AM	Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-20-25 10:02PM	OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential (Insider Monkey)
Jan-09-25 11:45AM	OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck (GlobeNewswire)
Dec-11-24 02:08AM	Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? (Insider Monkey)
Dec-10-24 08:00AM	NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer (PR Newswire)
Nov-29-24 02:43PM	Sleep Number, Getty Images, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-20-24 08:00AM	OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo (PR Newswire)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-14-24 06:00AM	NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results (PR Newswire)
Nov-08-24 04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01AM	OPKO Health Inc (OPK) Q3 2024 Earnings Call Highlights: A Turnaround in Profitability Amidst ... (GuruFocus.com)
Nov-07-24 10:15PM	Opko Health (OPK) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings (Zacks)
06:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
05:35PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch (GlobeNewswire)
Oct-29-24 04:05PM	OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire) +6.67% -5.00%
Oct-07-24 08:00AM	NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan (PR Newswire)
08:00AM	ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-23-24 08:00AM	OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development (GlobeNewswire)
Sep-16-24 07:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health (PR Newswire)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-08-24 12:14PM	OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down (Zacks) +11.72%
12:15AM	Opko Health (OPK) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-07-24 08:00PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:59PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-01-24 04:05PM	OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	OPKO Health Announces $100 Million Share Repurchase Program (GlobeNewswire) +7.04%
Jul-17-24 04:14PM	OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments (GlobeNewswire)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner (PR Newswire)
Jun-06-24 11:31AM	Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report? (Zacks)
May-31-24 10:48AM	OPKO Health to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 09:18AM	OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y (Zacks)
May-08-24 11:47AM	OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:44AM	OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-07-24 09:15PM	Opko Health (OPK) Q1 2024 Earnings Call Transcript (Motley Fool)
08:30PM	OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:09PM	OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
05:30PM	OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:38PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-03-24 08:00AM	OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-01-24 01:01PM	OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp (Zacks) +9.17%
Mar-28-24 11:08PM	Labcorp inks $237.5M buyout of Opkos reproductive, womens health testing assets (MedTech Dive) +12.15%
08:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business (PR Newswire)
Mar-25-24 09:57AM	OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 (Zacks)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire)
Mar-05-24 08:52AM	AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV (GlobeNewswire) -6.51%
Feb-29-24 08:31AM	OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:31AM	NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st (PR Newswire) -6.14%
09:02AM	OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top (Zacks)
06:18AM	Q4 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 09:00PM	Opko Health (OPK) Q4 2023 Earnings Call Transcript (Motley Fool) +5.37%
07:30PM	OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:08PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:43PM	OPKO Health Inc (OPK) Reports Fourth Quarter 2023 Results (GuruFocus.com)
04:05PM	OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Feb-26-24 09:16AM	Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks) +5.34%

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 10 '25	Buy	1.36	125,000	169,712	214,001,448	Apr 10 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 08 '25	Buy	1.48	125,000	184,650	213,876,448	Apr 08 05:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 01 '25	Buy	1.65	100,000	164,850	213,751,448	Apr 01 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 28 '25	Buy	1.70	150,000	254,385	213,651,448	Mar 28 05:22 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 17 '25	Buy	1.74	200,000	347,820	213,501,448	Mar 17 05:27 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '25	Buy	1.71	67,434	115,312	213,301,448	Feb 28 07:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 28 '25	Buy	1.47	47,537	70,060	213,234,014	Jan 28 05:40 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 17 '25	Buy	1.47	150,000	220,425	213,186,477	Jan 17 05:06 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 15 '25	Buy	1.48	500,000	740,850	213,036,477	Jan 15 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 13 '24	Buy	1.59	125,000	199,375	212,536,477	Dec 13 05:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 11 '24	Buy	1.56	500,000	781,050	212,411,477	Dec 11 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 29 '24	Buy	1.53	199,072	305,376	211,911,477	Nov 29 03:20 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 22 '24	Buy	1.59	100,000	159,000	211,712,405	Nov 22 05:17 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 14 '24	Buy	1.62	100,000	161,980	211,612,405	Nov 14 05:51 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 08 '24	Buy	1.50	280,183	421,535	211,512,405	Nov 08 05:40 PM
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
OPKO HEALTH, INC.	10% Owner	Aug 19 '24	Sale	34.49	50,000	1,724,520	2,646,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 16 '24	Sale	34.30	50,000	1,714,850	2,696,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 15 '24	Sale	33.08	39,824	1,317,505	2,746,972	Aug 19 05:23 PM
OPKO HEALTH, INC.	10% Owner	Aug 12 '24	Sale	33.95	59,787	2,029,811	2,811,783	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 13 '24	Sale	34.76	24,987	868,503	2,786,796	Aug 14 04:50 PM
OPKO HEALTH, INC.	10% Owner	Aug 08 '24	Sale	31.82	100,000	3,182,380	2,871,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Aug 06 '24	Sale	29.35	12,994	381,427	2,971,570	Aug 08 05:39 PM
OPKO HEALTH, INC.	10% Owner	Jul 31 '24	Sale	33.50	88,839	2,976,346	2,984,564	Aug 02 04:21 PM
OPKO HEALTH, INC.	10% Owner	Jul 29 '24	Sale	33.86	50,000	1,692,890	3,073,403	Jul 31 05:03 PM
OPKO HEALTH, INC.	10% Owner	Jul 24 '24	Sale	33.72	75,000	2,529,105	3,183,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 26 '24	Sale	33.85	60,000	2,031,258	3,123,403	Jul 26 07:49 PM
OPKO HEALTH, INC.	10% Owner	Jul 23 '24	Sale	33.46	75,000	2,509,245	3,258,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 22 '24	Sale	32.61	50,000	1,630,440	3,333,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 19 '24	Sale	32.29	25,000	807,250	3,383,403	Jul 23 05:16 PM
OPKO HEALTH, INC.	10% Owner	Jul 17 '24	Sale	32.93	25,000	823,188	3,408,403	Jul 19 06:46 PM
OPKO HEALTH, INC.	10% Owner	Jul 05 '24	Sale	28.24	36,118	1,020,016	3,433,403	Jul 09 04:07 PM
OPKO HEALTH, INC.	10% Owner	Jul 01 '24	Sale	26.63	50,000	1,331,700	3,508,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 02 '24	Sale	29.12	25,000	728,095	3,483,603	Jul 03 04:56 PM
OPKO HEALTH, INC.	10% Owner	Jul 03 '24	Sale	28.23	14,082	397,491	3,469,521	Jul 03 04:56 PM
FROST PHILLIP MD ET AL	CEO & Chairman	May 23 '24	Buy	1.27	100,000	126,937	211,232,222	May 23 08:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	May 17 '24	Buy	1.29	163,997	211,195	211,132,222	May 17 05:31 PM

BCDA

BioCardia Inc

OPK

Opko Health Inc

Upgrade your FINVIZ experience